IRT-103 in phase II clinical trials clinical trials showed
- Remission in 67% with 43% true Mucosal healing with endoscopies
- No-toxic side effect
- 505B(2) pathway FDA
- Immunomodulatory effect rather then a immunosupression drug
Cohn’s disease is a serious, chronic disease affecting the digestive system. Chronic means that the disease is long-term and persistent, usually lifelong. Crohn’s disease causes inflammation, most often in the small intestine (which has three parts: duodenum, jejunum, and ileum). The walls and lining of the affected areas become red and inflamed, leading to ulcers and bleeding. Crohn’s disease sometimes is named by referring to inflammation in the part of the intestine affected, such as Jejunoileitis, ileitis, ileocolitis, or colitis (when it involves the large intestine, also called the colon).
Crohn’s disease along with ulcerative colitis a similar illness is also called inflammatory bowel disease, or IBD. Crohn’s disease, can occur anywhere in the digestive tract, from mouth to the anus, attacks different sites in the intestine with areas of normal intestine in between, and affects the full thickness of the intestinal wall. Crohn’s and IBS go and go there are times when symptoms reappear or get worse (exacerbations or “flares”) and other periods when symptoms get better or go away altogether (“remission”).